Investments

Empowering innovators shaping the future of healthy aging
Philosophy

Our Philosophy

Impact Propelling a Healthier World

We play an actual impact role in healthspan innovation by embracing venture capital's core purpose: de-risking breakthrough ideas. We invest early, even at the idea or company creation stage, taking on more scientific and biological risks. By supporting research from the early steps to the commercialization phase, we pave the way for biotech investors to enter the healthspan space, positioning ourselves as intellectual leaders in healthspan investing.


Building a global ecosystem for change

Adding just one year of healthy lifespan translates into trillions of dollars in increased productivity and GDP. Achieving this vision requires collaboration and bringing together academicians, investigators, entrepreneurs, the biopharmaceutical industry, healthcare providers, policymakers, and regulators to translate discoveries into real-world, safe, and effective solutions. 

An inclusive approach
As a mission-driven organization, we take a pragmatic and inclusive approach, operating internationally without being bound to specific markets or purely philanthropic returns. We aim to extend healthspan for everyone in a way such that there is more equity and accessibility to therapies that help people live healthier, longer. At every step, we are guided by the highest standards of scientific integrity and ethics, ensuring that progress benefits humanity equitably and responsibly.

Read more Collapse
Strategy

Our Strategy

Driving impact through innovation

At Hevolution, we are driving the transition from today’s reactive “sick care” model to proactive healthcare through research and development that meets the highest international standards of science, ethics, and integrity. By increasing the breadth of knowledge in aging biology and translating discoveries into safe and effective solutions, we support existing companies and incubate new ones globally to create novel therapies.

 

A unique pragmatic and collaborative framework

We work closely with our world-class internal science and grantmaking teams to define broad scientific and investment strategies. Every investment is deeply diligent towards both its scientific rigor and commercial potential. As active venture investors, we collaborate alongside industry leaders, company founders, and other ecosystem players to ensure that real solutions with measurable impact are developed for patients and all stakeholders involved.

 

Long-term impact investment with a focus on aging biology

Our focus is on early-stage, programmatic investments in biotech companies that address the mechanisms of aging biology rather than specific diseases. However, we recognize the importance of treating high unmet medical needs today as a pathway to understanding aging at its core. Additionally, through our Breakthrough Innovation Alliance (BIA), we incubate companies with transformational ideas, ensuring they have the expertise, funding, and support to advance from ideation to commercialization.

Read More Collapse

Our Portfolio

Aeovian Pharmaceuticals
Clinical-stage biotech developing small molecules that restore cellular metabolic quality control in rare genetic and age-related diseases. 
 
 
Investment on
2024
Rubedo Life Sciences

Clinical-stage platform company developing first-in-class medicines targeting senescent cells that drive aging and disease.

Link to website
 

Investment on
2025
Tune Therapeutics

Clinical-stage platform company developing “tunable” genetic medicines for chronic and age-related conditions.

Link to website
 

Investment on
2025
Vandria SA

Clinical-stage Swiss biotech at the vanguard of mitochondrial therapeutics – developing mitophagy inducers for age-related diseases.

Link to website
 

Investment on
2024

Breakthrough Innovation Alliance (BIA ​​​​​​Venture)

Turning ideas into market-ready innovations

The BIA is our hands-on initiative to create and support companies advancing healthy aging. Unlike traditional accelerators, we convene a unique consortium of entrepreneurs-in-residence and pair capital with the practical mentorship and specialized expertise of biopharma leaders, VC investors, academics and CROs – together identifying and backing the best ideas in healthspan.


 

Read more Collapse
Asking the hard questions early
Success starts with focus. Before committing to creating a new company, we ask the tough questions upfront to filter only ideas with truly breakthrough potential. We work with entrepreneurs to design and fund litmus-test experiments that generate the proof-of-concept data needed to launch great companies and attract Seed through Series B funding.
Read more Collapse
Project Criteria
Every “BIA project” is focused on measurable outcomes and must meet three criteria: - A big idea with transformational potential in discovery, data insights, or therapeutics. - A clear healthspan focus with measurable impact. - A definable question that can be tested and answered within 12-18 months through targeted funding.
Read more Collapse
A more efficient way to build
Our approach increases the odds of success while eliminating wasted effort. Every company we incubate or start thereby launches with the right expertise, resources, and strategy in place – giving transformational ideas the conditions needed to thrive.
Read more Collapse